title: [Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis].
authors.forename: Hideki
authors.initials: H
authors.lastname: Tahara
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tsujimoto
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shouji
authors.forename: Masaaki
authors.initials: M
authors.lastname: Inaba
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tabata
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Nishizawa
mesh_terms: D015415:Biomarkers / Q000097:blood; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage; D003956:Dialysis / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008055:Lipids / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood*; D010760:Phosphorus Metabolism Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011073:Polyamines / Q000008:administration & dosage*; D000069603:Sevelamer
chemical_list: D015415:Biomarkers; D008055:Lipids; D010281:Parathyroid Hormone; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer; D002119:Calcium Carbonate; D002118:Calcium